Cansino Biologics Inc(688185) : recombinant novel coronavirus vaccine (adenovirus type 5 vector) has been included in the WHO emergency use list

Cansino Biologics Inc(688185) announcement, the World Health Organization (hereinafter referred to as “who”) disclosed on its official website on May 19, 2022 that the company’s recombinant novel coronavirus vaccine (adenovirus type 5 vector) kweisa was included in the “emergency use list”. The product is constructed by genetic engineering method. With replication defective human type 5 adenovirus as the vector, it can express the S antigen of novel coronavirus. It is intended to prevent diseases caused by novel coronavirus infection. At the same time, it does not contain preservatives, adjuvants and ingredients of animal origin.